Abstract
Much is now known about the physiology of platelets and their role in primary hemostasis; however, until recently far less was understood about their immediate precursors, marrow megakaryocytes (MKs). With the cloning and characterization of thrombopoietin (TPO), the principle regulator of the growth and development of MKs, research has been rapid and broad-based. In several laboratories TPO was cloned based on it’s binding to the product of the proto-oncogenec-mpl, at the time an orphan cytokine receptor, and was subsequently found to affect nearly all aspects of thrombopoiesis. Many of the molecular pathways that mediate TPO action have been explored. Like all other members of the hematopoietic cytokine receptor family upon hormone binding members of the JAK family of kinases are activated, which, in turn, phosphorylate the TPO receptor, generating docking sites for second messengers that affect multiple signaling pathways. Ultimately, cellular proliferative and anti-apoptotic mechanisms are initiated, increasing MK numbers, and a process termed endomitosis (EnM) begins, generating large, highly polyploid cells. The net result is the expansion of cells that give rise to mature platelets, a process that can be accentuated by the therapeutic administration of the hormone to thrombocytopenic patients.
Similar content being viewed by others
References
Souyri M, Vigon I, Penciolelli JF, Tambourin P, Wendling FA. Putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors.Cell 1990;63:1137–1147.
Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization ofMPL, the human homolog of thevmpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.Proc Natl Acad Sci USA. 1992;89:5640–5644.
Kaushansky K. Thrombopoietin: the primary regulator of platelet production.Blood. 1995;86:419–431.
Hill RJ, Levin J. Regulators of thrombopoiesis: Their biochemistry and physiology.Blood Cells. 1989;15:141–166.
Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early-acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.Blood. 1996;87:4544–4551.
Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.Blood. 1996;87:4998–5005.
Fox NE, Priestley GV, Papayannopoulou Th, Kaushansky K. Thrombopoietin (TPO) Expands Hematopoietic Stem Cells (HSCs)in vivo. Submitted for publication.
Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin.Nature. 1994;369:568–571.
Kaushansky K, Broudy VC, Grossmann A, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy.J Clin Invest. 1995;96:1683–1687.
Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC. Thrombopoietin expands erythroid, granulocytemacrophage and megakaryocytic progenitor cells in normal and myelosuppressed mice.Exp Hematol. 1996;23:265–269.
Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl.Blood. 1996;87:2162–2170.
Solar GP, Kerr WG, Zeigler FC, et al. Role of c-Mpl in early hematopoiesis.Blood. 1998;92:4–10.
Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K. Thrombopoietin induces PI3K and SHP2 activation through Gab and IRS proteins in BaF3 cells and primary murine megakaryocytes.J Biol Chem. 2001;276:2494–2502.
Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen activated protein kinase pathway in normal megakaryocytes: Role in endomitosis.Blood. 1999;94:1273–1282.
Geddis A, Kaushansky K. Inhibition of PI3K leads to a block in TPO-induced cell cycling at G1/S in both BaF3/Mpl cells and in primary megakaryocytic progenitors.Blood. 2000;96 (Suppl 1):539a
Vitrat N, Cohen-Solal K, Pique C, et al. Endomitosis of human megakaryocytes are due to abortive mitosis.Blood. 1998; 91:3711–3723.
Carow CE, Fox N, Kaushansky K. The Kinetics of Endomitosis in Primary Murine Megakaryocytes.J Cell Physiol. 2001; 188:291–303.
Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development.Cell. 1995;81:695–704.
Rojnuckarin P, Kaushansky K. Megakaryocyte proplatelet formation is dependent on PKCa.Blood. 2001;97:154–161.
Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.New Engl J Med. 1997;336:404–409.
Archimbaud E, Ottmann O, Liu Yin JA, et al. A randomised, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.Blood. 1999;94:3694–3701.
Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.Blood. 2001;98:1346–1351
Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates heamtopoietic recovery following high-dose chemotherapy.Blood. 1999;93:2798–2806.
Author information
Authors and Affiliations
About this article
Cite this article
Kaushansky, K. Thrombopoietin: from theory to reality. Int J Hematol 76 (Suppl 1), 343–345 (2002). https://doi.org/10.1007/BF03165282
Issue Date:
DOI: https://doi.org/10.1007/BF03165282